AI Article Synopsis
- - Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that doesn’t express key receptors (ER, PR, HER2), leading to poor outcomes and limited treatment options.
- - Recent developments in immunotherapy, such as antibody-based drugs and CAR-T cells, show potential for more effective treatment against TNBC by targeting its unique immune characteristics.
- - Experts believe that novel immunotherapies could significantly improve the management of TNBC, addressing the ongoing challenges of treating this difficult cancer type.
Article Abstract
Introduction: Triple-negative breast cancer (TNBC) is a subtype of severely aggressive breast cancer that lacks the expression of oestrogen receptor (ER), progesterone receptor and human epidermal growth factor receptor 2 (HER2) and is highly metastatic and related to a poor prognosis. Current standard treatments are still limited to systemic chemotherapy, radiotherapy, and surgical resection. More effective treatments are urgently needed.
Areas Covered: The immunogenicity of TNBC has provided opportunities for the development of targeted immunotherapy. In this review, we focus on the recent development in antibody-based drug modalities, including angiogenesis inhibitors, immune checkpoint inhibitors, antibody-drug conjugates, immunoconjugates, T cell-redirecting bispecific antibodies and CAR-T cells, and their mechanisms of action in TNBC.
Expert Opinion: At present, the treatment of TNBC is still a major challenge that needs to be addressed. Novel immunotherapies are promising opportunities for improving the management of this aggressive disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17425247.2022.2093853 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!